

**Drug Analysis Print**  
**Drug name: THYROID**

[Jump to first report page](#)

<b>Drug name:</b>	THYROID	<b>Report type:</b>	Spontaneous
<b>Report run date:</b>	11-Dec-2012	<b>Report origin:</b>	UNITED KINGDOM
<b>Data lock date:</b>	10-Dec-2012 22:52:27	<b>Route of admin:</b>	ALL
<b>Period covered:</b>	01-Jul-1963 to 10-Dec-2012	<b>Reporter type:</b>	ALL
<b>Earliest reaction date:</b>	21-Nov-2012	<b>Reaction:</b>	ALL
<b>MedDRA version:</b>	MedDRA 15.1	<b>Age group:</b>	ALL

<b>Total number of reactions*:</b>	2	<b>Total number of ADR reports:</b>	1	<b>Total number of fatal ADR reports:</b>	0
------------------------------------	---	-------------------------------------	---	---	---

**Products included in this print - Single active constituent products (PBGs):**  
THIROYD

**Drug Analysis Print**  
**Drug name: THYROID**

<b>Drug name:</b>	THYROID	<b>Report type:</b>	Spontaneous
<b>Report run date:</b>	11-Dec-2012	<b>Report origin:</b>	UNITED KINGDOM
<b>Data lock date:</b>	10-Dec-2012 22:52:27	<b>Route of admin:</b>	ALL
<b>Period covered:</b>	01-Jul-1963 to 10-Dec-2012	<b>Reporter type:</b>	ALL
<b>Earliest reaction date:</b>	21-Nov-2012	<b>Reaction:</b>	ALL
<b>MedDRA version:</b>	MedDRA 15.1	<b>Age group:</b>	ALL

System Organ Class	Single active constituent		Multiple active constituent		Total unique reports*	
	All	Fatal	All	Fatal	All	Fatal
Cardiac disorders	1	0	0	0	1	0
General disorders	1	0	0	0	1	0

<b>TOTAL NUMBER OF REACTIONS</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>
----------------------------------	----------	----------	----------	----------	----------	----------

<b>TOTAL NUMBER OF FATAL ADR REPORTS*</b>		<b>0</b>		<b>0</b>		<b>0*</b>
<b>TOTAL NUMBER OF ADR REPORTS*</b>	<b>1</b>		<b>0</b>		<b>1*</b>	

\*This provides the number of individual reports and may be less than the sum of the single-active constituent and multi-active constituent columns. For example, if both a single- and multi-active constituent product are considered by the reporter to have a suspected causal relationship with the suspected reaction, then the same report will appear in both columns.

# Drug Analysis Print

## Drug name: THYROID

<b>Drug name:</b>	THYROID	<b>Report type:</b>	Spontaneous
<b>Report run date:</b>	11-Dec-2012	<b>Report origin:</b>	UNITED KINGDOM
<b>Data lock date:</b>	10-Dec-2012 22:52:27	<b>Route of admin:</b>	ALL
<b>Period covered:</b>	01-Jul-1963 to 10-Dec-2012	<b>Reporter type:</b>	ALL
<b>Earliest reaction date:</b>	21-Nov-2012	<b>Reaction:</b>	ALL
<b>MedDRA version:</b>	MedDRA 15.1	<b>Age group:</b>	ALL

### Glossary/Abbreviations

**ADR** - Adverse Drug Reaction

**Age group** - lists which age groups are included in the Drug Analysis Print – either ALL, Adolescent, Adult, Child, Elderly, Infant or Neonate

**Data lock date** - shows data on the database at this specified date and time

**HLT** - High Level Term - see definition of MedDRA

**MedDRA** - this stands for **Medical Dictionary for Regulatory Activities**, which is the internationally agreed list of terms used for Medicines Regulation. MedDRA groups related adverse drug reaction terms in a hierarchical structure whereby the '*preferred term*' (*PT*) (e.g. tunnel vision) is grouped under the broader heading the '*high level term*' (*HLT*) (e.g. visual field disorders). '*High level terms*' are contained within the '*system organ class*' (*SOC*) (e.g. eye disorders). The '*preferred term*' is the most specific term on the Drug Analysis Print, while the '*system organ class*' is the most general

**Multi active constituent products** - contain the drug constituent of interest plus one or more other drug constituents (e.g. co-codamol contains paracetamol and codeine)

**NEC** - appears in MedDRA and stands for Not Elsewhere Classified

**NOS** - appears in MedDRA and stands for Not Otherwise Specified

**PBG** - Product Brand Group – this means drug brand name e.g. Amoxil is a PBG for the drug substance amoxicillin

**Products included in this print** - this is a list of the products for which at least one suspected Adverse Drug Reaction (ADR) report has been received that specifies that product as a 'suspected drug' (i.e. suspected causal association with the reaction). It does not provide an exhaustive list of the products which contain the named drug substance

**PT** - Preferred Term - see definition of MedDRA

**Reaction** - defines which ADRs are included in the Drug Analysis Print – either ALL, Serious or Non-Serious

**Reporter type** - lists the reporter types which are included in the Drug Analysis Print – either Patient, Health Professional or ALL (i.e. both)

**Report run date** - the date the Drug Analysis Print was produced

**Route of admin** - lists the route of administration of the suspect drug for which reports are included in the Drug Analysis Print, e.g. ORAL only includes reports where the suspect drug was specified as having been taken by the oral route, or ALL which includes all routes of administration

**Single active constituent products** - contain only the drug substance of interest

**Spontaneous** - suspected ADR reports sent in to the Yellow Card Scheme are called spontaneous reports

**Substance** - is an active ingredient in a product

**Substance Variant** - is a more specific substance term. A substance may have zero, one or many linked variants. For example LITHIUM is linked to the variant LITHIUM CARBONATE and LITHIUM CITRATE.

**System Organ Class (SOC)** - this is the highest level in MedDRA which groups together reactions that affect similar systems/organs in the body

**Drug Analysis Print**  
**Drug name: THYROID**

<b>Drug name:</b>	THYROID	<b>Report type:</b>	Spontaneous
<b>Report run date:</b>	11-Dec-2012	<b>Report origin:</b>	UNITED KINGDOM
<b>Data lock date:</b>	10-Dec-2012 22:52:27	<b>Route of admin:</b>	ALL
<b>Period covered:</b>	01-Jul-1963 to 10-Dec-2012	<b>Reporter type:</b>	ALL
<b>Earliest reaction date:</b>	21-Nov-2012	<b>Reaction:</b>	ALL
<b>MedDRA version:</b>	MedDRA 15.1	<b>Age group:</b>	ALL

Reaction Name	Single active constituent		Multiple active constituent		Total unique reports*	
	All	Fatal	All	Fatal	All	Fatal
<b>SOC</b>						
<i>HLT</i>						
PT						
<b>Cardiac disorders</b>						
<i>Supraventricular arrhythmias</i>						
Atrial fibrillation	1	0	0	0	1	0
<b>Cardiac disorders SOC TOTAL</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>

\*This provides the number of individual reports and may be less than the sum of the single-active constituent and multi-active constituent columns. For example, if both a single- and multi-active constituent product are considered by the reporter to have a suspected causal relationship with the suspected reaction, then the same report will appear in both columns.

**Drug Analysis Print**  
**Drug name: THYROID**

<b>Drug name:</b>	THYROID	<b>Report type:</b>	Spontaneous
<b>Report run date:</b>	11-Dec-2012	<b>Report origin:</b>	UNITED KINGDOM
<b>Data lock date:</b>	10-Dec-2012 22:52:27	<b>Route of admin:</b>	ALL
<b>Period covered:</b>	01-Jul-1963 to 10-Dec-2012	<b>Reporter type:</b>	ALL
<b>Earliest reaction date:</b>	21-Nov-2012	<b>Reaction:</b>	ALL
<b>MedDRA version:</b>	MedDRA 15.1	<b>Age group:</b>	ALL

Reaction Name	Single active constituent		Multiple active constituent		Total unique reports*	
	All	Fatal	All	Fatal	All	Fatal
<b>SOC</b>						
<i>HLT</i>						
PT						
<b>General disorders</b>						
<i>Product quality issues NEC</i>						
Product quality issue	1	0	0	0	1	0
<b>General disorders SOC TOTAL</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>

<b>TOTAL NUMBER OF REACTIONS</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>
----------------------------------	----------	----------	----------	----------	----------	----------

<b>TOTAL NUMBER OF FATAL ADR REPORTS*</b>		<b>0</b>		<b>0</b>		<b>0*</b>
<b>TOTAL NUMBER OF ADR REPORTS*</b>	<b>1</b>		<b>0</b>		<b>1*</b>	

\*This provides the number of individual reports and may be less than the sum of the single-active constituent and multi-active constituent columns. For example, if both a single- and multi-active constituent product are considered by the reporter to have a suspected causal relationship with the suspected reaction, then the same report will appear in both columns.